Fig. 5: AR alterations in metastatic castration-resistant prostate cancer (mCRPC). | BJC Reports

Fig. 5: AR alterations in metastatic castration-resistant prostate cancer (mCRPC).

From: Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project

Fig. 5

a AR mutations, amplification, and rearrangement in F1LCDx® at pre-treatment in mCRPC (n = 95) are indicated. Each colored circle represents a single mutation with variant allele frequency (VAF) and copy number. b Change of VAF of AR mutation (left) and copy number of AR gene (right) in paired ctDNA at pre-treatment (blue bar) and post-treatment (red bar) from matched patients. c Time to treatment failure according to treatment (abiraterone or enzalutamide) (left), and AR gene alterations (right) in mCRPC patients.

Back to article page